ReviewACS infectious diseases2018
The Human Milk Glycome as a Defense Against Infectious Diseases: Rationale, Challenges, and Opportunities.
Review in ACS infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Milk phospholipid-coated lipid droplets modulate the infant gut microbiota and metabolome influencing weight gain.Microbiome · 2025Trial
- Trial
- Distinctive Patterns of GutNutrients · 2026Article
- Shaping of the Infant Gut Microbiome by Milk Oligosaccharides.Annual review of biochemistry · 2026Review
- Chemical Synthesis of Human Milk Oligosaccharides: Sialyllacto-The Journal of organic chemistry · 2025Article
- Chemical Synthesis of Two Fucosylated Human Milk Oligosaccharides: 3-Fucosyllactose and Lacto-N-fucopentaose V.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Cellular respiration and amino acid metabolism is altered by dietary oligosaccharides inFrontiers in microbiology · 2025Article
- Glycosyltransferases: glycoengineers in human milk oligosaccharide synthesis and manufacturing.Frontiers in molecular biosciences · 2025Review
- Human Milk Oligosaccharides: Decoding Their Structural Variability, Health Benefits, and the Evolution of Infant Nutrition.Nutrients · 2024Review
- NMR Studies of the Interactions between Sialyllactoses and the Polysialytransferase Domain for Polysialylation Inhibition.Current issues in molecular biology · 2024Article
- Linking human milk oligosaccharide metabolism and early life gut microbiota: bifidobacteria and beyond.Microbiology and molecular biology reviews : MMBR · 2024Review
- Human milk oligosaccharides and the association with microbiota in colostrum: a pilot study.Archives of microbiology · 2024Article
- Interactions of human milk oligosaccharides with the immune system.Frontiers in immunology · 2024Review
- Characterising glycosaminoglycans in human breastmilk and their potential role in infant health.Microbial cell (Graz, Austria) · 2024Article
- Key biologically active components of breast milk and their beneficial effects.Seminars in pediatric surgery · 2023Review
- Review
- In silico analysis of the human milk oligosaccharide glycome reveals key enzymes of their biosynthesis.Scientific reports · 2022Article
- Antibiofilm Activity of Human Milk Oligosaccharides against Multidrug Resistant and Susceptible Isolates ofACS infectious diseases · 2021Article
- Malnutrition and Gut Microbiota in Children.Nutrients · 2021Review
- Digestion, fermentation, and pathogen anti-adhesive properties of the hMO-mimic di-fucosyl-β-cyclodextrin.Food & function · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Each year over 3 million people die from infectious diseases with most of these deaths being poor and young children who live in low- and middle-income countries. Infectious diseases emerge for a multitude of reasons. On the social front, reasons include a breakdown of public health standards, international travel, and immigration (for financial, civil, and social reasons). At the molecular level, the modern rise of infectious diseases is tied to the juxtaposition of drug-resistant pathogens and a lack of new antimicrobials. The consequence is the possibility that humankind will return to the preantibiotic era wherein millions of people will perish from what should be trivial illnesses. Given the stakes, it is imperative that the chemistry community take leadership in delivering new antibiotic leads for clinical development. We believe this can happen through innovation in two areas. First is the development of novel chemical scaffolds to treat infections caused by multidrug-resistant pathogens. The second area, which is not exclusive to the first, is the generation of antibiotics that do not cause collateral damage to the host or the host's microbiome. Both can be enabled through advances in chemical synthesis. It is with this general philosophy in mind that we hypothesized human milk oligosaccharides (HMOs) could serve as novel chemical scaffolds for antibacterial development. We provide herein a personal account of our laboratory's progress toward the goal of using HMOs as a defense against infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.